| Bioactivity | Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines[1]. |
| In Vivo | Sonrotoclax (compound 1; 5-50 mg/kg; p.o.; 每日一次, 持续 42 天; 患有急性淋巴细胞白血病 (ALL) 异种移植物的雌性 NCG 小鼠) 具有抗肿瘤活性并抑制肿瘤生长[1]。 Animal Model: |
| Name | Sonrotoclax |
| CAS | 2383086-06-2 |
| Formula | C49H59N7O7S |
| Molar Mass | 890.10 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1. |
Sonrotoclax
CAS: 2383086-06-2 F: C49H59N7O7S W: 890.10
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety o
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.